Taivex received US FDA Investigational New Drug Application (IND) Approval for T-1301 on June 17, 2021, to initiate phase I clinical trial for the treatment of advanced solid tumors. T-1301 is a small molecular oral anti-cancer drug licensed from National Health Research Institutes in 2019. After completion of pre-clinical safety evaluation, as well as chemistry, manufacture and control of drug …

Following IND approval by the US FDA in Mid-January, 2021, Taivex submitted the Phase I clinical trial application to the Taiwan FDA later on January 29 and received approval on April 12. The anticipated initiation of the Phase I trial remains by middle of 2021. T-1201 Phase I trial is a multi-centered study in Taiwan, will enroll advanced solid tumor …

Taivex received US FDA Investigational New Drug Application (IND) Approval for T-1201 on December 15, 2020, to initiate phase I clinical trial for the treatment of advanced solid tumors. T-1201 is a small molecular IV anti-cancer drug licensed from National Health Research Institutes in 2016. After completion of pre-clinical safety evaluation, as well as chemistry, manufacture and control of drug …

T-1101 is a First-in-Class Hec1/Nek2 inhibitor that disrupts cancer cell cycle division thereby inhibits tumor growth in the body and receives TFDA approval to initiate Phase I clinical study in Taiwan. Patients with advanced tumors have been enrolled into an ongoing open-label, Phase I dose escalation study in Taiwan. Enrollment for this study in Taiwan started in Jan, 2021. Trial …